Moricizine

Structural formula
General
Non-proprietary name	Moricizine
other names	N - [10- (3-Morpholin-4-ylpropanoyl) phenothiazin-2-yl] ethyl carbamate
Molecular formula	C 22 H 25 N 3 O 4 S (Moricizine) ; C 22 H 25 N 3 O 4 S HCl (Moricizine hydrochloride ) ;
External identifiers / databases
EC number	250-854-5
ECHA InfoCard	100.046.216
PubChem	34633
DrugBank	DB00680
Wikidata	Q904071
Drug information
ATC code	C01 BG01
Drug class	Antiarrhythmic
properties
Molar mass	427.52 g mol −1 (Moricizine) ; 463.98 g mol −1 (Moricizine hydrochloride) ;
Melting point	156–157 ° C (Moricizine) ; 189 ° C (decomposition) (Moricizine hydrochloride) ;
pK s value	6.4 (moricizine)
solubility	soluble in water and ethanol (Moricizine hydrochloride)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
Toxicological data	36 mg kg −1 ( LD 50 , mouse , iv , hydrochloride) ; 12 mg kg −1 ( LD 50 , rat , iv , hydrochloride) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Moricizine is a drug from the group of antiarrhythmics that is used to treat cardiac arrhythmias . As a sodium channel blocker with no effect on the duration of the action potential , it is counted in class Ic of the Vaughan / Williams classification. Moricizin is no longer approved in Europe.

Possible paradoxical proarrhythmic effects of moricizin are feared since the CAST study observed a significant reduction in ventricular extrasystoles , but an insignificant increase in overall mortality from 5.4 to 7.2 percent.

Individual evidence

^ ^A ^b ^c ^d ^e ^f The Merck_Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1082, ISBN 978-0-911910-00-1 .
↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
^ The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction . N Engl J Med (1992) 327: 227-233, PMID 1377359 .

[MERCK_Index-1] A ^b ^c ^d ^e ^f The Merck_Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1082, ISBN 978-0-911910-00-1 .

[NV-2] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[3] The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction . N Engl J Med (1992) 327: 227-233, PMID 1377359 .